Your child may go home with a small pump running blinatumomab (Blincyto) around the clock. This page is about the practical side: what to ask before you leave, how insurance approval usually works, and where families can ask about help paying. It is not medical advice. Your care team decides the treatment plan.
For the hospital bills, charity care, and other drug-assistance programs, see Financial Assistance Programs and Questions to ask the hospital financial counselor and social worker.
What blinatumomab is
NCI describes blinatumomab (brand name Blincyto) as an immunotherapy that brings T cells and leukemia cells close together so the T cells can kill the leukemia cells. It binds to a protein called CD3 on T cells and a protein called CD19 on B cells.
On June 14, 2024, the FDA approved blinatumomab for adult and pediatric patients one month and older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia in the consolidation phase of multiphase chemotherapy. The current FDA label, posted on DailyMed, also includes uses in relapsed or refractory disease and in some patients whose cancer is in remission but who still have a small number of remaining leukemia cells (minimal residual disease). Whether this medicine is right for your child is a question for the care team.
A Children’s Oncology Group phase 3 trial, AALL1731, studied adding blinatumomab to chemotherapy for children with newly diagnosed standard-risk B-ALL. The results were published in the New England Journal of Medicine and are summarized by COG. This page does not tell you whether your child should receive it.
Some families first heard about blinatumomab in a letter. On July 18, 2024, COG wrote to families on AALL1732, its study for newly diagnosed high-risk B-ALL. The letter says the update is based on results from other studies, not AALL1732, in which adding blinatumomab to chemotherapy led to fewer relapses than chemotherapy alone for many patients. It says COG was stopping AALL1732 for some patients so that those in the high-risk group could have blinatumomab added to their chemotherapy. It gives different guidance for the two risk groups in the study, and it says the treating doctor is in the best position to guide treatment and to decide the timing. Here is a scanned copy of the letter one family received: COG letter to AALL1732 families, July 18, 2024 (PDF, 2 pages). It is a 2024 letter about one study at one point in time. Only your child’s care team can say what, if anything, applies to your child now.
Why it often means a pump at home
The FDA label says blinatumomab is given as a continuous intravenous infusion at a constant flow rate using an infusion pump. The manufacturer’s patient page explains that one cycle is usually 4 weeks of infusion followed by 2 weeks without infusion, and that treatment starts in the hospital. After that, the doctor decides whether the rest of the cycle can continue at home with a small portable pump, or in a clinic or infusion center. A health care professional changes the bag on a schedule the team sets. Who decides: your care team.
Questions to ask the care team before you go home
Ask these before you leave, and write down the answers, including names and numbers. Your team may already have a handout or a letter. If they do, use that. This is a list of questions, not a set of instructions.
- Can we have a written letter to take to an emergency room that explains the infusion, the pump, and how to reach our team? Can we keep a copy in the car?
- Who supplies the home pump, and what is that company’s 24-hour phone number?
- What should we do if the infusion stops or the pump alarms, and how quickly should we call? The manufacturer’s patient page tells families to contact their health care provider if there is a problem with the pump. Ask your team what they want you to do.
- If our child has a port, which needle does this infusion use?
- Do you want us to keep a written log of start and stop times?
- What temperature or other sign means we should call, and what is the after-hours or on-call number? Put that number in your phone before you leave.
- When and where is the next bag change, and who does that work?
Insurance and prior authorization
This medicine, and the home infusion that often goes with it, commonly needs approval before it starts. Our Treatment Cost Overview already notes that blinatumomab and home infusion often need prior authorization.
Who does the work: the hospital’s prior-authorization or financial team, sometimes with a specialty pharmacy. You can help by asking, early: “Has prior authorization for blinatumomab and for the home infusion been submitted, and is anything still waiting?” Who decides: your insurer, using its own rules. If a request is denied, see Insurance Navigation for how to appeal. A denial is not the last word, but the program, not this page, decides the outcome.
Help paying
Two Amgen programs may apply, depending on the type of insurance you have. Eligibility is not a promise. Ask the hospital financial counselor or specialty pharmacy to help you enroll. Our Financial Assistance Programs page also lists these programs, along with help for other drugs.
If you have commercial or private insurance (for example, insurance through an employer, or a plan you buy yourself): The Amgen SupportPlus Co-Pay Program may help eligible patients lower out-of-pocket costs for the medicine, including deductible, coinsurance, and copay, up to program limits. The official page says there is no income requirement, that eligible patients may pay as little as $0 per dose or cycle, and that eligibility criteria and program maximums apply. It is not valid if Medicare, Medicaid, or another federal or state health program pays for the prescription in whole or in part, and it is not valid for cash-paying patients. Enroll online at that page, or call 866-264-2778 (Monday through Friday, 9 a.m. to 8 p.m. Eastern time, as listed on the co-pay page). Have your insurance information ready. Who decides: Amgen SupportPlus. Who does the work: you or a caregiver enroll, and the doctor’s office or specialty pharmacy often helps process the card, as the official page describes.
If you have no insurance coverage for the medicine, or the plan excludes it: The Amgen Safety Net Foundation is a nonprofit patient assistance program that may provide Amgen medicines at no cost to people who qualify. The eligibility page says you may qualify if you have lived in the United States or its territories for six months or longer, you meet income limits that vary by product, and you have no insurance coverage. For certain products, some Medicare patients with an affordability gap may also be considered. Do not guess the income limit; check the official page for the product, or ask the financial counselor to check with you. Apply through the Foundation’s how to apply page. The Foundation says it does not charge patients a fee to apply. Who decides: the Amgen Safety Net Foundation. Who does the work: you and the doctor’s office complete the application; the hospital financial counselor can help.
If you have Medicaid or Medicare, ask the financial counselor what, if anything, is left after those programs, and whether another fund can help. The co-pay card above does not apply when a government program is paying.
A home-pump day checklist
Use this as a reminder of what to have on hand, based on the answers your team already gave you. It is not a substitute for their instructions.
- ☐ The written emergency-room letter, plus a copy in the car
- ☐ The pump supplier’s 24-hour phone number, saved in your phone
- ☐ The clinic or on-call number, and the fever or “call now” rule your team gave you
- ☐ The port needle type, if your team wrote that down
- ☐ A start and stop log, if your team asked you to keep one
- ☐ The next bag-change time and place
- ☐ A way to reach the financial counselor or specialty pharmacy if a shipment, authorization, or co-pay question comes up
If something about the pump does not look right, call the number your team told you to use. Do not change pump settings unless your team has told you to.
What this guide can and can’t do
This page helps you know what to ask, whom to call, and where to apply for help paying. It is not medical, legal, or financial advice, and it is not a treatment recommendation. Eligibility, deadlines, and coverage are set by your care team, your insurer, and each assistance program, and they can change. If a deadline is not listed here from an official source, do the step as soon as you can.
Programs change. If a link here is out of date, tell us so we can fix it for the next family.
Related guides
- Treatment Cost Overview
- Financial Assistance Programs
- Insurance Navigation
- Questions to Ask the Hospital Financial Counselor and Social Worker
Sources
Each link was opened and checked on November 17, 2026.
- Blinatumomab, National Cancer Institute (updated February 13, 2025)
- FDA approves blinatumomab as consolidation for CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia, U.S. Food and Drug Administration, June 14, 2024
- BLINCYTO (blinatumomab) prescribing information, DailyMed (label updated April 14, 2026)
- What to expect when receiving BLINCYTO, Amgen
- Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children, New England Journal of Medicine (AALL1731, ClinicalTrials.gov NCT03914625)
- Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children, Children’s Oncology Group
- Amgen SupportPlus Co-Pay Program, Amgen
- BLINCYTO Patient Support Program, Amgen SupportPlus
- Amgen Safety Net Foundation, Amgen Safety Net Foundation
- Eligibility, Amgen Safety Net Foundation
- How to apply, Amgen Safety Net Foundation
- About, Amgen Safety Net Foundation
- Letter to participants and families with B-ALL on study AALL1732, Children’s Oncology Group, July 18, 2024 (scanned copy of the letter one family received)
